Quantum BioPharma Ltd. (NASDAQ: QNTM) has entered a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, marking a significant milestone for the company and potentially for the treatment landscape of progressive MS. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business, leveraging its extensive expertise in clinical trial execution.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. This matters because progressive forms of MS currently have limited treatment options, and Lucid-MS represents a novel approach. As an investigational, first-in-class New Chemical Entity, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. If successful, this mechanism could address the underlying cause of MS progression, rather than just managing symptoms.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. The compound is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The initiation of this Phase 2 trial follows promising preclinical data and represents a crucial step toward potentially bringing a new therapy to patients. For investors, this agreement de-risks the operational aspects of the trial and underscores the company's commitment to advancing its pipeline. The latest updates on QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.
The broader implications of this announcement extend beyond Quantum BioPharma. The collaboration with Thermo Fisher, a global leader in clinical research services, lends credibility and operational strength to the trial. It also highlights the growing interest in neuroprotective strategies for neurodegenerative diseases. For a sector constantly seeking breakthroughs, Lucid-MS's novel mechanism targeting PAD2 could pave the way for a new class of MS therapies. As the trial progresses, the data will be closely watched by researchers, clinicians, and investors alike. To view the full press release, visit https://ibn.fm/CZH9U.
BioMedWire (BioMedWire) is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. This infrastructure ensures that news like Quantum BioPharma's trial advancement reaches a wide audience of investors and industry stakeholders. For full terms of use, see the disclaimer at https://www.BioMedWire.com/Disclaimer.
